Galmed Pharmaceuticals (GLMD) Payables (2013 - 2025)

Galmed Pharmaceuticals' Payables history runs 13 years deep, the most recent figure standing at $2.0 million for Q4 2025.

• In Q4 2025, Payables rose 53.13% year-over-year to $2.0 million; the TTM figure through Dec 2025 stood at $2.0 million (up 53.13% YoY), while the FY2025 annual figure was $2.0 million, up 53.13% from the prior year.
• Payables was $2.0 million for Q4 2025 at Galmed Pharmaceuticals, up from $1.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $5.8 million in Q1 2021 to a low of $106000.0 in Q1 2023.
• Historically, Payables has averaged $2.6 million across 5 years, with a median of $1.9 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Payables sank 99.93% in 2021, then jumped 1204.72% in 2024.
• A 5-year view of Payables shows it stood at $4.9 million in 2021, then tumbled by 47.44% to $2.6 million in 2022, then fell by 26.6% to $1.9 million in 2023, then tumbled by 30.39% to $1.3 million in 2024, then jumped by 53.13% to $2.0 million in 2025.
• The last three Payables figures came in at $2.0 million (Q4 2025), $1.7 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.